Biogen Inc (BIIB)

245.00
0.00(0.00%)
  • Volume:
    13
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    227.74 - 227.74
Trading near 52-week Low

Biogen has hit the lowest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

BIIB Overview

Prev. Close
245
Day's Range
227.74-227.74
Revenue
-
Open
227.74
52 wk Range
227.74-245
EPS
14.01
Volume
13
Market Cap
28.7B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
13
P/E Ratio
14.81
Beta
0.425
1-Year Change
-23.15%
Shares Outstanding
145,113,047
Next Earnings Date
Oct 25, 2022
What is your sentiment on Biogen?
or
Market is currently closed. Voting is open during market hours.

Biogen Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Biogen Inc Analysis

Biogen Inc Company Profile

Biogen Inc Company Profile

Employees
9100
  • Type:Equity
  • Market:Chile
  • ISIN:US09062X1037

Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.

Read More

Analyst Price Target

Average239.69 (+21.19% Upside)
High320
Low185
Price197.78
No. of Analysts26
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
Daily
Weekly
Monthly
Moving Averages
Technical Indicators
Summary
  • same named company is also listen in indian market.. Biogen
    1
    • Waiting for a breakthrough !A great entry point now , as I think , I bought 220 , I think the rocket is fueled here . Just be smarter , dump on time , otherwise you will become a bag holder
      1
      • Samsung!
        2
        • 01708620849
          0
          • is better to buy RTX US defense company . don't risk your money in Biogen .
            0
            • still a good moment to buy?
              4
              • yes
                1
              • is better to buy RTX US defense company . don't risk your money in Biogen .
                2
              • maybe
                0
            • what is going on with this
              1
              • 2021.07.15 - RB Best Buy @$324
                0
                • wow
                  0
                  • Any action for the price soon
                    0